CD274 and neoplasm: The prespecified biomarker analyses comprised PD-L1 and CD73 IHC status prospectively assessed prior randomization on the most recent tumor tissue available (baseline metastatic (n = 82), baseline primary (n = 30), or archived primary tumor (n = 15) in case the baseline tissue was not evaluable) (Supplementary Table 2).